StockData
Johnson & Johnson logo

Johnson & Johnson (JNJ) operating KPIs

JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)

Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%

Johnson & Johnson cARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%) (%)

Form 8-K EX-99.2 Segment Sales Schedule

QuarterlyAnnual
Latest, Q3 2026
19.4%
Period ended Sep 30, 2026
Change on a year earlier
-33.9 pts
53.3% in Q3 2025
History
9 quarters
Since Q1 2023
Sources
9
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%) (%)Year on yearSource
Q3 2026Sep 30, 202619.4%-33.9 ptsForm 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Q2 2026Jun 28, 202631.7%–Form 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗
Q1 2026Mar 29, 202636.2%–Form 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗
Q4 2025Dec 28, 202538.2%–Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Q3 2025Sep 28, 202553.3%-31.6 ptsForm 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗
Q3 2024Sep 29, 202484.9%–Form 8-K (a2024q3exhibit991.htm, filed 2024-10-15) ↗
Q2 2024Jun 30, 202446.5%–Form 8-K (a2024q2exhibit991.htm, filed 2024-07-17) ↗
Q1 2024Mar 31, 202499.8%+44.8 ptsForm 8-K (a2024q1exhibit991.htm, filed 2024-04-16) ↗
Q1 2023Apr 2, 202355.0%–Form 8-K (a2023q1exhibit991.htm, filed 2023-04-18) ↗

Cite this data

StockData. (2026). Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%) (%), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_carvykti_us_ops_yoy

See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.